Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | GJB2 | P29033 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8443464 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL736485 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL5029670 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL1134708 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL182764 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL9291634 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL23646744 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL8940690 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL258033 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL4912663 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090068151-A1 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium | CELL GENESYS, INC. | 2009-03-12 | — | — | US | disclosed |
| US-7459154-B2 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium | CELL GENESYS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080241105-A1 | Method and reagents for the enhancement of virus transduction in the bladder epithelium | CELL GENESYS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080138322-A1 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium | CELL GENESYS, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080112931-A1 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium | CELL GENESYS, INC. | 2008-05-15 | — | — | US | disclosed |
| US-20080112932-A1 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium | CELL GENESYS, INC. | 2008-05-15 | — | — | US | disclosed |
| US-20080076703-A1 | Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium | CELL GENESYS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-7267815-B2 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium | CELL GENESYS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| CN-1753618-A | Methods and reagents for the enhancement of virus transduction in the bladder epithelium | CELL GENESYS INC (US) | 2006-03-29 | — | — | CN | disclosed |
| EP-1583502-A2 | METHODS AND REAGENTS FOR THE ENHANCEMENT OF VIRUS TRANSDUCTION IN THE BLADDER EPITHELIUM | CELL GENESYS, INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050059613-A1 | Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium | CELL GENESYS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005007101-A2 | COMPOSITIONS AND METHODS FOR THE ENHANCED UPTAKE OF THERAPEUTIC AGENTS THROUGH THE BLADDER EPITHELIUM | CELL GENESYS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040176318-A1 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium | CG ONCOLOGY, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004060303-A2 | METHODS AND REAGENTS FOR THE ENHANCEMENT OF VIRUS TRANSDUCTION IN THE BLADDER EPITHELIUM | CELL GENESYS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040131590-A1 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium | CG ONCOLOGY, INC. | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059613-A1 | Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium | MUC1, SLC17A5, CD44 | GBA1 433/4885SLC2A1 138/4885MAPK1 3210/4885 |
| US-20080076703-A1 | Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium | MUC1, SLC17A5, CD44 | GBA1 433/4885SLC2A1 138/4885MAPK1 3210/4885 |
| US-20090068151-A1 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium | EGFR, MUC1, PLAUR | GBA1 1299/4885SLC2A1 4244/4885MAPK1 1411/4885 |
| US-20080112932-A1 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium | EGFR, MUC1, PLAUR | GBA1 1299/4885SLC2A1 4244/4885MAPK1 1411/4885 |
| US-20040131590-A1 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium | EGFR, MUC1, PLAUR | GBA1 1299/4885SLC2A1 4244/4885MAPK1 1411/4885 |
| US-20080138322-A1 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium | EGFR, MUC1, PLAUR | GBA1 1299/4885SLC2A1 4244/4885MAPK1 1411/4885 |
| US-20040176318-A1 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium | EGFR, MUC1, PLAUR | GBA1 1299/4885SLC2A1 4244/4885MAPK1 1411/4885 |
| US-20080241105-A1 | Method and reagents for the enhancement of virus transduction in the bladder epithelium | EGFR, MUC1, PLAUR | GBA1 1200/4885SLC2A1 4309/4885MAPK1 1188/4885 |
| US-20080112931-A1 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium | EGFR, MUC1, PLAUR | GBA1 1299/4885SLC2A1 4244/4885MAPK1 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.